| Literature DB >> 23658698 |
Brooks A Fallis1, Irfan A Dhalla, Jason Klemensberg, Chaim M Bell.
Abstract
BACKGROUND: Medication non-adherence frequently leads to suboptimal patient outcomes. Primary non-adherence, which occurs when a patient does not fill an initial prescription, is particularly important at the time of hospital discharge because new medications are often being prescribed to treat an illness rather than for prevention.Entities:
Mesh:
Year: 2013 PMID: 23658698 PMCID: PMC3642181 DOI: 10.1371/journal.pone.0061735
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Identification of study patients.
Descriptive characteristics of study patients.
| Total number of patients (n,%) | 232 |
|
| 78±7.9 |
|
| |
| Male | 113 (49%) |
| Female | 119 (51%) |
|
| |
| All | 10 (7–13.25) |
| Standing | 9 (6–12) |
| PRN | 1 (0–2) |
|
| |
| All | 2.1±1.5 |
| Standing | 1.8±1.3 |
| PRN | 0.3±0.6 |
|
| |
| Standing & PRN | 44 (19%) |
| Standing only | 177 (76%) |
| PRN only | 11 (5%) |
|
| 6 days (4–9) |
|
| |
| Home | 197 (85%) |
| Long-term care | 35 (15%) |
|
| 195 (84%) |
|
| |
| ED++ or Hospital within 30 days | 63 (27%) |
| Hospital within 30 days | 42 (18%) |
Sd = standard deviation. + IQR = interquartile range. ** PCP = Primary care physician. ++ ED = Emergency department.
Characteristics of study patients divided by primary medication adherence at 7 days after discharge.
| Adherent at 7 days | Non-adherent at 7 days | |
| Total number of patients (n,%) | 166 (72%) | 66 (28%) |
|
| 77.7±8.0 | 78.8±7.6 |
|
| ||
| Male | 79 (48%) | 34 (52%) |
| Female | 87 (52%) | 32 (48%) |
|
| ||
| All | 10 (7–13.75) | 10.5 (8.25–13) |
| Standing | 9 (6–12.75) | 10 (7.25–12) |
| PRN | 1 (0–1) | 1 (0–2) |
|
| ||
| All | 2.0±1.5 | 2.4±1.5 |
| Standing | 1.7±1.3 | 2.0±1.3 |
| PRN | 0.2±0.5 | 0.5±0.7 |
|
| ||
| Standing & PRN | 25 (15%) | 19 (29%) |
| Standing only | 134 (81%) | 43 (65%) |
| PRN only | 7 (4%) | 4 (6%) |
|
| 5 days (4–8) | 7 days (4–11) |
|
| ||
| Home | 146 (88%) | 51 (77%) |
| Long-term care | 2 (12%) | 15 (23%) |
|
| 138 (83%) | 57 (86%) |
|
| ||
| ED++ or Hospital within 30 days | 49 (30%) | 14 (21%) |
| Hospital within 30 days | 34 (20%) | 8 (12%) |
Sd = standard deviation. + IQR = interquartile range. ** PCP = Primary care physician. ++ ED = Emergency department.
Prescription adherence at 7 and 30 days after hospital discharge.
| Filled prescription at 7 d (n,%) | Filled prescription at 30 d (n,%) | |
|
| ||
| Adherent | 166 (72%) | 177 (76%) |
| Non-adherent | 66 (28%) | 55 (24%) |
|
| ||
| Adherent | 83 (75%) | 89 (81%) |
| Non-adherent | 27 (25%) | 21 (19%) |
|
| ||
| Adherent | 47 (76%) | 48 (77%) |
| Non-adherent | 15 (24%) | 14 (23%) |
|
| ||
| Adherent | 29 (59%) | 33 (67%) |
| Non-adherent | 20 (41%) | 16 (33%) |
|
| ||
| Adherent ** | 186 (80%) | 195 (84%) |
| Non-adherent | 46 (20%) | 37 (16%) |
Adherent patients picked up all medications, while non-adherent patients failed to pick-up at least 1 medication. +“Important” medications exclude PRN, symptom control, dermatological, and supplements. **Adherent to “important medications means either fully adherent or non-adherent to medications not classified as "important".
Medications to which patients exhibited primary non-adherence.
| Drug Category and indication | Prescriptions | Specific Medications (n) |
|
| ||
| Pneumonia | 4 | Levofloxacin (2), azithromycin (1), cefuroxime (1) |
| COPD exacerbation | 2 | Azithromycin (1) cefuroxime (1) |
| Cellulitis | 5 | Cephalexin (1), ciprofloxacin (1), cloxacillin (2), levofloxacin (1) |
| Urinary tract infection | 5 | Ciprofloxacin (5) |
|
| 2 | Metronidazole (1), vancomycin (1) |
| Other | 5 | Amoxicillin (1), clarithromycin (1), dapsone (1), ofloxacin eye drops (1), valacyclovir (1) |
|
| ||
| Upper gastrointestinal bleed | 4 | Pantoprazole (1), omeprazole (2), pantoprazole (1) |
| Gastrointestinal bleed prophylaxis | 2 | Pantoprazole (2) |
| Gastroesophageal reflux | 2 | Pantoprazole (1), rabeprazole (1) |
|
| ||
| Stroke (secondary prevention) | 5 | Atorvastatin (3), clopidogrel (2) |
| Coronary artery disease (secondary prevention) | 4 | Atorvastatin (2), metoprolol (1), nitroglycerin SL (1) |
| Heart failure | 3 | Bisoprolol (1), ramipril (1), furosemide (1) |
| Venous thromboembolism | 1 | Warfarin (1) |
|
| ||
| Chronic obstructive pulmonary disease | 8 | Prednisone (3), salbutamol (3), Advair discus (1), tiotropium (1) |
|
| ||
| Diabetes mellitus | 2 | Humalog (1), Humulin 30/70 (1) |
| Osteoporosis | 1 | Risedronate (1) |
| Other | 2 | Fludrocortisone (1), leuprolide acetate (1) |
|
| ||
| Nausea | 4 | Ondansetron (4) |
| Constipation | 14 | Sennosides (6), docusate sodium (4), lactulose (4) |
| Pain | 8 | Hydromorphone (3), morphine (3), oxycodone & acetaminophen (2) |
| Dementia associated behavioural problems | 4 | Risperidone (2), quetiapine (1), trazodone (1) |
|
| ||
| Nutritional supplements (iron, folate) | 5 | Ferrous fumarate (2), ferrous gluconate (1), folate (2) |
| Topical dermatologic treatments | 3 | Betamethasone valerate (1), hydrocortisone acetate and urea (1), mupirocin (1) |
| Other + | 5 | Acetazolamide (1), colchicine (1), primidone (1), tamsulosin (1), verapamil (1) |
|
|
|
Other antibiotics: PCP prophylaxis (dapsone), H.pylori (amoxicillin & clarithromycin), herpes zoster (valacyclovir), eye infection (ofloxacin drops). + Other: Migraines (verapamil), tremor (primidone), benign prostatic hypertrophy (tamsulosin), bicarbonate (acetazolamide), gout (colchicine).